Benjamin F. Edwards & Company’s Alnylam Pharmaceuticals ALNY Stock Holding History

Benjamin F. Edwards & Company’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$87K	Sell	356 -48	-12%	-$7.58K	﹤0.01%	1145
2024 Q1	$60K	Buy	404 +33	+9%	+$5.5K	﹤0.01%	1241
2023 Q4	$71K	Buy	+371	New	+$63.2K	﹤0.01%	1168
2023 Q1	–	Sell	-1,321	Closed	-$314K	–	1776
2022 Q4	$314K	Buy	+1,321	New	+$282K	0.01%	590
2022 Q3	–	Sell	-28	Closed	-$4K	–	1814
2022 Q2	$4K	Hold	28	–	–	﹤0.01%	1563
2022 Q1	$5K	Hold	28	–	–	﹤0.01%	1500
2021 Q4	$5K	Buy	28 +11	+65%	+$2.04K	﹤0.01%	1504
2021 Q3	$3K	Buy	17 +2	+13%	+$375	﹤0.01%	1583
2021 Q2	$3K	Buy	+15	New	+$2.2K	﹤0.01%	1571
2018 Q4	–	Sell	-32	Closed	-$3K	–	1686
2018 Q3	$3K	Sell	32 -10	-24%	-$1.01K	﹤0.01%	1460
2018 Q2	$4K	Buy	42 +15	+56%	+$1.49K	﹤0.01%	1437
2018 Q1	$3K	Hold	27	–	–	﹤0.01%	1467
2017 Q4	$3K	Hold	27	–	–	﹤0.01%	1423
2017 Q3	$3K	Hold	27	–	–	﹤0.01%	1380
2017 Q2	$2K	Hold	27	–	–	﹤0.01%	1360
2017 Q1	$1K	Hold	27	–	–	﹤0.01%	1303
2016 Q4	$1K	Buy	+27	New	+$1.13K	﹤0.01%	1194

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Benjamin F. Edwards & Company's ALNY Position: Q2 2024 in Review

Benjamin F. Edwards & Company reduced its Alnylam Pharmaceuticals (ALNY) stake by 12% in Q2 2024, selling an estimated $7.58K and leaving 356 shares worth $87K. The position accounts for ﹤0.01% of the portfolio, ranked #1145.

Benjamin F. Edwards & Company first reported a position in ALNY in Q4 2016 and has held it in 17 quarters since. The position peaked at $314K in Q4 2022. 523 funds tracked by Wall St. Rank hold ALNY as of Q2 2024.

Benjamin F. Edwards & Company held 356 shares of Alnylam Pharmaceuticals worth $87K as of Q2 2024.
Benjamin F. Edwards & Company sold 48 Alnylam Pharmaceuticals shares in Q2 2024, an estimated $7.58K.
Alnylam Pharmaceuticals made up ﹤0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #1145 holding.
Benjamin F. Edwards & Company first reported a position in Alnylam Pharmaceuticals in Q4 2016 and has held it in 17 quarters since.
Benjamin F. Edwards & Company's Alnylam Pharmaceuticals position peaked at $314K in Q4 2022.
523 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.